Meeting
2020 Gastrointestinal Cancers Symposium
Exploratory analysis of trifluridine/tipiracil in late-stage metastatic colorectal cancer (mCRC): Prognostic factors.
Authors
Meinolf Karthaus
Hematology, Oncology, and Palliative Medicine, Klinikum Neuperlach and Harlaching, Munich, Germany
Meinolf Karthaus , B Hoell , G Zaun , M Guyot , Martin H. Schuler , Stefan Kasper
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 24)
Abstract #
24
Poster Bd #
A18
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Exploratory analysis of the effect of FTD/TPI in patients treated in RECOURSE by prognostic factors.
First Author: Josep Tabernero
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic factors of patients (pts) with salvage-line metastatic colorectal cancer (mCRC).
First Author: Hideaki Bando
Poster
2021 ASCO Annual Meeting
Patient-reported quality of life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Interim results of the TALLISUR study.
First Author: Meinolf Karthaus
Poster
2020 Gastrointestinal Cancers Symposium
Clinical impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) treated with regorafenib or trifluridine/tipiracil as later-line.
First Author: Hiromichi Nakajima